Cipla
Cipla Limited, a leading global pharmaceutical company headquartered in India, has been a pioneer in the healthcare industry since its establishment in 1935. With a strong presence in over 80 countries, Cipla focuses on developing a wide range of generic medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Renowned for its commitment to affordable healthcare, Cipla has made significant strides in areas such as respiratory, cardiovascular, and anti-retroviral therapies. The company is distinguished by its innovative approach to drug development and its robust pipeline of products, which cater to diverse therapeutic needs. Cipla's market position is bolstered by its extensive distribution network and strategic partnerships, making it a trusted name in the pharmaceutical sector. With numerous accolades for its contributions to global health, Cipla continues to lead the way in providing high-quality, accessible medicines.
DitchCarbon Score
How does Cipla's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cipla's score of 42 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cipla's reported carbon emissions
Cipla, headquartered in India, has made significant strides in addressing its carbon emissions, with a commitment to achieving carbon neutrality by December 2025. In 2023, the company reported total emissions of approximately 4,577,672,000 kg CO2e across all scopes, with Scope 1 emissions at about 37,398,000 kg CO2e, Scope 2 emissions at approximately 207,238,000 kg CO2e, and a substantial Scope 3 total of around 4,576,772,000 kg CO2e. In previous years, Cipla's emissions have shown variability. For instance, in 2022, the company recorded Scope 1 emissions of about 38,355,000 kg CO2e and Scope 2 emissions of approximately 201,676,000 kg CO2e. The 2021 figures indicated Scope 1 emissions of around 41,617,000 kg CO2e and Scope 2 emissions of about 201,676,000 kg CO2e. Cipla's climate commitments focus on enhancing energy efficiency and increasing the use of renewable energy sources, including electricity and biofuels, across its operations. The company has set specific targets for its India manufacturing operations to achieve carbon neutrality for Scope 1 and Scope 2 emissions by the end of 2025. Overall, Cipla's proactive approach to reducing its carbon footprint reflects its dedication to sustainability and environmental responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 236,358,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,013,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cipla is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
